---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000093"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:16:19.663553+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics stockholders elect three Class III directors and approve say-on-pay at 2025 annual meeting

## Summary
- 84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.
- Non-binding advisory say-on-pay approved: 19.7M for, 157k against, 2.0M broker non-votes.
- Ratification of Ernst & Young as independent auditor for FY2025 approved: 21.8M for, 6k against.

## SEC filing metadata
- accession: 0001453687-25-000093
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000093/0001453687-25-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000093/rnac-20250613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000093
- JSON: https://secwatch.observer/filing/0001453687-25-000093.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.